-
Price Target For Charles River Laboratories Revised Downwards (CRL)
Tuesday, August 3, 2010 - 1:22pm | 113Jeffries & Company has reduced its price target for Charles River Laboratories (NYSE: CRL) from $37.00 to $33.00. Charles River Laboratories has implemented a stock buyback which is to be funded by existing cash, credit, and free cash flows. Based on the fact that the Company did not fully use...
-
Piper: Solid Near-Term Support For WX Share Price
Tuesday, August 3, 2010 - 1:11pm | 175Analysts at Piper Jaffray reinstate coverage of WuXi AppTec Inc (NYSE: WX) with a "neutral" rating, while raising their estimates for the company. The target price for WX is set to $16. Piper Jaffray says, “We believe WX fundamentals remain largely unchanged following the termination of merger...
-
Charles River Falls 4% After Missing Estimates (CRL)
Monday, August 2, 2010 - 2:59pm | 185Shares of Charles River Laboratories International (NYSE: CRL) are currently down 3.99% at $29.84 per share during Monday afternoon trading. Today's trading range for shares of Charles River Laboratories International has been between $29.06 and $30.50 per share. The consensus price target of...
-
Jefferies & Co. Reiterates Hold on Bruker Corp. (BRKR)
Monday, August 2, 2010 - 10:53am | 167Jefferies & Co. is out with a research report this morning, where it reiterates its Hold rating on Bruker Corp. (NASDAQ: BRKR); it has a $15.00 price target on the stock. The Jefferies analysts said that they are raising estimates on the name with 2010 EPS at $0.60 from $0.57, following BRKR's...
-
Charles River Scraps WuXi Takeover Bid
Friday, July 30, 2010 - 5:40am | 135Citing investor opposition, Charles River Laboratories (NYSE: CRL) is scrapping its $1.6 billion takeover offer for China's WuXi PharmaTech (NYSE: WX). The deal would have been the largest takeover of a Chinese company by a foreign firm. Charles River, a provider of research and testing services to...
-
JANA Partners Urges All Charles River Shareholders to Vote Against Proposed WuXi Acquisition
Thursday, July 29, 2010 - 4:04pm | 85JANA Partners today urged all stockholders of Charles River Laboratories International, Inc. (NYSE: CRL) to vote against the issuance of shares needed to complete the proposed acquisition of WuXi PharmaTech (Cayman) Inc. (NYSE: WX), and against giving Charles River the right to adjourn next week's...
-
It Could be Worse - You Got Vistaprinted! (VPRT)
Thursday, July 29, 2010 - 2:42pm | 961The market has turned very choppy as we encounter many multiple cross winds on the charts - you have 1100 as a line in the sand, with S&P 1093/1094 being the exponential 50/200 day moving averages below... but 1113, the 200 day simple moving average above... and then a Fibonacci level up there...
-
DARK HORSE HEDGE
Thursday, July 29, 2010 - 2:01pm | 935DARK HORSE HEDGE By Scott at Sabrient and Ilene at Phil’s Stock World Cover short AMAG at the Market, Thursday 7/29/10 Short RAIL at the Market, Thursday 7/29/10 AMAG lived up to expectations last night with a resounding -$1.01 versus expectations of -$.96 and revenues fell slightly short at a not-...
-
Lack Of Recovery In Toxicology Prompts CVD To Reduce Guidance Further
Thursday, July 29, 2010 - 10:38am | 147Analysts at William Blair & Co maintain their "outperform" rating on Covance Inc (NYSE: CVD), while reducing their estimates for the company. William Blair & Co says, “Second-quarter EPS of $0.49 were two cents above our estimate and in line with consensus; excluding 9 cents of...
-
Piper Jaffray Reiterates Neutral on Pharmaceutical Product Development (PPDI)
Thursday, July 29, 2010 - 10:26am | 124Piper Jaffray is out with a research report this morning, where it reiterates its Neutral rating on Pharmaceutical Product Development (NASDAQ: PPDI); it has a $28.00 price target on the stock. The PJ analysts cited the company’s most recent earnings report, which was “decent,” though encompassed...
-
Covance Reports Second Quarter Revenue of $475M and EPS of $0.49
Wednesday, July 28, 2010 - 4:29pm | 88Covance Inc. (NYSE: CVD) today reported earnings per diluted share for its second quarter ended June 30, 2010 of $0.49, including $0.09 of facility rationalization and other cost reduction actions during the second quarter, versus $0.60 in the first quarter of 2010 and $0.67 in the second quarter...
-
Top Narrow Based Indexes For July 28 (AFFX, HTM, STBUY)
Wednesday, July 28, 2010 - 1:31pm | 190By 1:13 pm, the Dow Jones Industrial Average was down 0.22 points, or 0.00%, to 10,537.47, while the broader Standard & Poor's 500 index had lost 2.21 points, or 0.20%. The NASDAQ composite index fell 10.87 points, or 0.48%. Some of the narrow based indexes supporting the markets are Genetic...
-
ILMN’s Quarter Results Show That Array Consumables Are Back With A Bang
Wednesday, July 28, 2010 - 10:09am | 193Analysts at Piper Jaffray reiterate their "overweight" rating on Illumina Inc (NASDAQ: ILMN), while raising their estimates for the company. The target price for ILMN has been raised from $47 to $54. ILMN reported better-than-expected Q2 earnings. Piper Jaffray mentions, “Encouragingly, array...
-
Benzinga’s Top Pre-Market NASDAQ Gainers (BWLD, CHRW, ILMN, AONE)
Wednesday, July 28, 2010 - 8:36am | 123Buffalo Wild Wings Inc (NASDAQ: BWLD) rose 8.32% to $44.25 in the pre-market session. BWLD had reported better-than-expected Q2 earnings yesterday. CH Robinson Worldwide Inc (NASDAQ: CHRW) added 6.21% to $65 in pre-market trading. CHRW’s Q2 profits exceeded the Street view. Illumina Inc (NASDAQ:...
-
Illumina Beats; Shares Pop (ILMN)
Tuesday, July 27, 2010 - 5:17pm | 121Illumina Inc. (NASDAQ: ILMN) reports Q2 earnings of $0.26 versus estimates of $0.23. Illumina Inc. reports Q2 revenues of $212 million versus estimates of $193.89 million. Revenues increased 31.2% year over year. The company said that FY2010 EPS would be in the range of $0.93 to $1.00 on revenues...